Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
09 2019
Historique:
received: 22 12 2018
accepted: 16 04 2019
pubmed: 6 6 2019
medline: 2 6 2020
entrez: 6 6 2019
Statut: ppublish

Résumé

miR-410-3p plays opposite roles in different cancers and may act as an oncomiR or tumor suppressor miR. The purpose of this study was to assess the role of miR-410-3p in somatotroph, gonadotroph, and corticotroph pituitary adenomas. Tissue samples were obtained from 75 patients with pituitary adenoma. miR-410-3p expression was assessed using qRT-PCR performed on RNA isolated from fresh frozen samples. In vitro experiments were performed on cell lines derived from somatotroph (GH3), gonadotroph (RC-4B/C), and corticotroph (AtT-20) pituitary tumors. Cells were transfected with synthetic mimic of miR-410-3p or non-targeting scrambled-miR control. Subsequently, proliferation assays and transwell invasion assays were performed. The expression of cyclin D1, E1, and B1 in cells after transfection was determined using qRT-PCR. The activation of MAPK, PTEN/AKT and STAT3 signaling pathways were assessed using western blot. We have found that the level of expression of miR-410-3p differs in particular types of pituitary adenomas. miR-410-3p significantly upregulates proliferation and invasiveness of RC-4B/C and AtT-20 cells, while inhibiting GH3 cells. We observed that the levels of cyclin B1 upon transfection with miR-410-3p mimic were increased in RC-4B/C and AtT-20, yet decreased in GH3 cells. We have shown that miR-410-3p promoted the activation of MAPK, PTEN/AKT, and STAT3 signaling pathways in RC-4B/C and AtT-20 cells, but suppressed their activity in GH3 cells. miR-410-3p acts as an oncomiR in gonadotroph and corticotroph adenoma cells, while as a tumor suppressor miR in somatotroph adenoma cells.

Identifiants

pubmed: 31165412
doi: 10.1007/s12020-019-01960-7
pii: 10.1007/s12020-019-01960-7
pmc: PMC6717603
doi:

Substances chimiques

Cyclins 0
Gonadotropins 0
MIRN410 microRNA, human 0
MicroRNAs 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Oncogene Protein v-akt EC 2.7.11.1
Mitogen-Activated Protein Kinases EC 2.7.11.24
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-655

Subventions

Organisme : Narodowe Centrum Nauki
ID : UMO-2016/23/N/NZ5/02597
Pays : International
Organisme : Warszawski Uniwersytet Medyczny
ID : 1M15/PM1/17
Pays : International

Références

Int J Endocrinol. 2014;2014:435171
pubmed: 25548562
Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):629-639
pubmed: 27923456
Oncogene. 2011 Apr 21;30(16):1880-91
pubmed: 21170085
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
Biomed Pharmacother. 2018 May;101:585-590
pubmed: 29518604
EMBO J. 1995 May 1;14(9):1878-91
pubmed: 7743995
Oncogene. 2005 Nov 14;24(50):7443-54
pubmed: 16288291
Clin Cancer Res. 2018 Nov 15;24(22):5757-5766
pubmed: 29980532
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
J Clin Endocrinol Metab. 2010 Oct;95(10):E181-91
pubmed: 20668041
Cell Cycle. 2015;14(16):2590-7
pubmed: 26125663
Cell Physiol Biochem. 2016;39(1):303-15
pubmed: 27351906
Nat Rev Endocrinol. 2011 May;7(5):257-66
pubmed: 21423242
Med Sci Monit. 2017 Mar 13;23:1277-1285
pubmed: 28288092
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
J Cell Physiol. 2007 Feb;210(2):370-7
pubmed: 17111382
Endocrine. 2017 Oct;58(1):184-189
pubmed: 28808880
Oncol Res. 2013;21(3):129-36
pubmed: 24512727
BMC Med Genet. 2017 Jul 14;18(1):72
pubmed: 28709401
Mol Cell Endocrinol. 2018 Mar 5;463:87-96
pubmed: 28445712
J Clin Endocrinol Metab. 2010 Apr;95(4):1708-16
pubmed: 20164287
Endocrine. 2018 May;60(2):308-316
pubmed: 29080043
J Clin Invest. 2015 Apr;125(4):1692-702
pubmed: 25774503
J Neurooncol. 2017 Sep;134(2):253-258
pubmed: 28577032
Endocrine. 2012 Oct;42(2):285-91
pubmed: 22552912
Pituitary. 2017 Aug;20(4):450-463
pubmed: 28432562
Endocr Pathol. 2013 Mar;24(1):11-9
pubmed: 23296986
Histol Histopathol. 2016 Aug;31(8):911-20
pubmed: 26842619
Endocrine. 2010 Aug;38(1):67-75
pubmed: 20960104
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2459-2465
pubmed: 29969630
Endocrine. 2018 Dec;62(3):663-680
pubmed: 30066286
Nat Rev Cancer. 2002 Nov;2(11):836-49
pubmed: 12415254
Cell Physiol Biochem. 2017;44(2):792-803
pubmed: 29176323
Mol Cell Biol. 2005 Jul;25(13):5725-37
pubmed: 15964826
Am J Pathol. 2011 Oct;179(4):2120-30
pubmed: 21871428
Front Endocrinol (Lausanne). 2016 Jan 11;6:188
pubmed: 26793165
EMBO Mol Med. 2012 Mar;4(3):143-59
pubmed: 22351564
Cell Res. 2008 Feb;18(2):254-67
pubmed: 18227858
Mol Cell Endocrinol. 2017 Nov 15;456:51-61
pubmed: 28089822
Endocrine. 2013 Dec;44(3):735-43
pubmed: 23576023
Eur J Cancer. 2012 Feb;48(3):389-95
pubmed: 22119203
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Endocr Relat Cancer. 2009 Dec;16(4):1329-38
pubmed: 19620247
Mol Cell Biol. 1997 Nov;17(11):6508-16
pubmed: 9343414
J Cell Biochem. 2018 Nov;119(11):8737-8742
pubmed: 30086210
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Endocrine. 2019 Apr;64(1):147-156
pubmed: 30474823
Oncotarget. 2017 Apr 25;8(17):29269-29281
pubmed: 28418928
Curr Biol. 2000 Jan 13;10(1):47-50
pubmed: 10660304
Oncol Lett. 2018 Feb;15(2):1655-1663
pubmed: 29434861
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):389-401
pubmed: 28871006
Neuroendocrinology. 1991 Sep;54(3):267-73
pubmed: 1944812
Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96
pubmed: 22473468
Tumour Biol. 2016 Oct;37(10):13469-13477
pubmed: 27465551
Pituitary. 2015 Oct;18(5):710-21
pubmed: 25862551
Biochem Genet. 2016 Apr;54(2):107-19
pubmed: 26718581
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5987-5993
pubmed: 30280781
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Tomasz M Grzywa (TM)

Center for Preclinical Research, The Department of Methodology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.

Klaudia Klicka (K)

Center for Preclinical Research, The Department of Methodology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.

Beata Rak (B)

Center for Preclinical Research, The Department of Methodology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland. beata.rak@wum.edu.pl.
Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland. beata.rak@wum.edu.pl.
Postgraduate School of Molecular Medicine, Warsaw, Poland. beata.rak@wum.edu.pl.
The Department of Internal Diseases and Endocrinology, Public Central Teaching Hospital, Medical University of Warsaw, 1A Banacha Str., 02-097, Warsaw, Poland. beata.rak@wum.edu.pl.

Dawid Mehlich (D)

Center for Preclinical Research, The Department of Methodology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, 2C Banacha Str., 02-097, Warsaw, Poland.

Filip Garbicz (F)

Center for Preclinical Research, The Department of Methodology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Postgraduate School of Molecular Medicine, Warsaw, Poland.
Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, 14 Indiry Gandhi Str., 02-776, Warsaw, Poland.

Grzegorz Zieliński (G)

The Department of Neurosurgery, Military Institute of Medicine, 128 Szaserów Str., 04-141, Warsaw, Poland.

Maria Maksymowicz (M)

The Department of Pathology and Laboratory Diagnostics, M. Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 Roentgena Str., 02-781, Warsaw, Poland.

Emir Sajjad (E)

Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
The Department of Neurosurgery, Military Institute of Medicine, 128 Szaserów Str., 04-141, Warsaw, Poland.

Paweł K Włodarski (PK)

Center for Preclinical Research, The Department of Methodology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.
Center for Preclinical Research, The Department of Histology and Embryology, Medical University of Warsaw, 1B Banacha Str., 02-097, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH